AEMD · Insider Trading
AETHLON MEDICAL INC
Every open-market purchase and sale reported by AEMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | Edward G Broenniman | Director | F | −218 | −$1.42K |
| 2026-10-15 | Chetan Shah | Director | F | −436 | −$2.84K |
| 2026-10-15 | Angela Rossetti | Director | A | +21,815 | +$49.96K |
| 2026-10-15 | Steven P Larosa | Chief Medical Officer | A | +42,000 | — |
| 2026-10-15 | Nicolas Gikakis | Director | F | −436 | −$2.84K |
| 2026-10-13 | James B Frakes | CFO/CEO | A | +42,000 | — |
| 2026-07-01 | Chetan Shah | Director | F | −2,182 | −$1.79K |
| 2026-07-01 | Edward G Broenniman | Director | F | −1,091 | −$895 |
| 2026-07-01 | Nicolas Gikakis | Director | F | −2,182 | −$1.79K |
| 2026-04-21 | Nicolas Gikakis | Director | A | +21,815 | +$49.96K |
| 2026-04-21 | Edward G Broenniman | Director | A | +21,815 | +$49.96K |
| 2026-04-21 | Angela Rossetti | Director | A | +21,815 | +$49.96K |
| 2026-04-21 | Chetan Shah | Director | A | +21,815 | +$49.96K |
| 2026-04-01 | Edward G Broenniman | Director | F | −89 | −$195 |
| 2026-04-01 | Chetan Shah | Director | F | −178 | −$390 |
| 2026-04-01 | Nicolas Gikakis | Director | F | −178 | −$390 |
| 2026-01-02 | Chetan Shah | Director | F | −179 | −$496 |
| 2026-01-02 | Nicolas Gikakis | Director | F | −179 | −$496 |
| 2026-01-02 | Edward G Broenniman | Director | F | −89 | −$247 |
| 2025-10-02 | Nicolas Gikakis | Director | F | −1,786 | −$1.34K |
| 2025-10-02 | Chetan Shah | Director | F | −1,786 | −$1.34K |
| 2025-10-02 | Edward G Broenniman | Director | F | −893 | −$669 |
| 2025-07-01 | Nicolas Gikakis | Director | F | −1,786 | −$2.14K |
| 2025-07-01 | Edward G Broenniman | Director | F | −893 | −$1.07K |
| 2025-07-01 | Chetan Shah | Director | F | −1,786 | −$2.14K |
| 2025-04-25 | Chetan Shah | Director | A | −142,857 | −$51.14K |
| 2025-04-25 | Edward G Broenniman | Director | A | +142,857 | +$50.00K |
| 2025-04-25 | Angela Rossetti | Director | A | +142,857 | +$50.00K |
| 2025-04-25 | Nicolas Gikakis | Director | A | +142,857 | +$50.00K |
| 2025-04-01 | Nicolas Gikakis | Director | F | −3,289 | −$1.18K |
| 2025-04-01 | Edward G Broenniman | Director | F | −1,645 | −$589 |
| 2025-04-01 | Chetan Shah | Director | F | −3,289 | −$1.18K |
| 2025-01-03 | Edward G Broenniman | Director | F | −1,645 | −$1.41K |
| 2025-01-03 | Chetan Shah | Director | F | −3,289 | −$2.83K |
| 2025-01-03 | Nicolas Gikakis | Director | F | −3,289 | −$2.83K |
| 2024-10-01 | Nicolas Gikakis | Director | F | −3,289 | −$1.53K |
| 2024-10-01 | Chetan Shah | Director | F | −3,289 | −$1.53K |
| 2024-10-01 | Edward G Broenniman | Director | F | −1,645 | −$767 |
| 2024-07-01 | Nicolas Gikakis | Director | F | −5,244 | −$2.62K |
| 2024-07-01 | Edward G Broenniman | Director | F | −1,645 | −$821 |
| 2024-07-01 | Chetan Shah | Director | F | −3,289 | −$1.64K |
| 2024-04-17 | Nicolas Gikakis | Director | A | +32,894 | +$50.00K |
| 2024-04-17 | Chetan Shah | Director | A | +32,894 | +$50.00K |
| 2024-04-17 | Edward G Broenniman | Director | A | +32,894 | +$50.00K |
| 2024-04-17 | Angela Rossetti | Director | A | +32,894 | +$50.00K |
| 2024-04-01 | Chetan Shah | Director | F | −1,163 | −$1.95K |
| 2024-04-01 | Nicolas Gikakis | Director | F | −1,954 | −$3.28K |
| 2024-04-01 | Edward G Broenniman | Director | F | −1,163 | −$1.95K |
| 2024-01-02 | Chetan Shah | Director | F | −1,163 | −$2.55K |
| 2024-01-02 | Nicolas Gikakis | Director | F | −1,954 | −$4.28K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James B Frakes | CFO/CEO | 42,063 | $216.62K |
| Steven P Larosa | Chief Medical Officer | 42,057 | $216.59K |
| Angela Rossetti | Director | 4,846 | $24.96K |
| Edward G Broenniman | Director | 4,313 | $22.21K |
| Chetan Shah | Director | 3,787 | $19.50K |
| Nicolas Gikakis | Director | 3,784 | $19.49K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AEMD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.